HealthCo Healthcare and Wellness REIT (ASX: HCW) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

HealthCo Healthcare and Wellness REIT Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $456.65 million
P/E Ratio 67.62
Dividend Yield 9.59%
Shares Outstanding 550.18 million
Earnings per share -0.007
Dividend per share 0.08
Year To Date Return -18.63%
Earnings Yield 1.48%
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

HealthCo Healthcare and Wellness REIT (ASX: HCW)
Latest News

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Share Market News

Goldman Sachs just added this ASX healthcare share to its conviction buy list

This healthcare share could be a strong buy..

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
REITs

The HCW (ASX:HCW) share price has gained 15% since the REIT's IPO

Here's how the healthcare-focused REIT has performed on the ASX so far .

Read more »

Motley Fool Chief Investment Officer Scott Phillips on nine news
Motley Fool Media

Fortescue's big fall, job ad numbers disappoint and rates in focus. Scott Phillips on Nine's Late News

Fortescue shareholders, including Twiggy Forrest, are to enjoy a massive payday which explained the fall in the Fortescue share price…

Read more »

Frequently Asked Questions

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
30 Dec 2024 $0.0210 0.00% Final 26 Feb 2025
27 Sep 2024 $0.0210 0.00% Interim 22 Nov 2024
27 Jun 2024 $0.0200 0.00% Final 22 Aug 2024
27 Mar 2024 $0.0200 0.00% Interim 22 May 2024
28 Dec 2023 $0.0200 0.00% Interim 21 Feb 2024
28 Sep 2023 $0.0200 0.00% Interim 29 Nov 2023
29 Jun 2023 $0.0200 0.00% Final 30 Aug 2023
01 May 2023 $0.0188 0.00% Interim 23 Jun 2023
29 Dec 2022 $0.0188 0.00% Interim 24 Feb 2023
29 Sep 2022 $0.0188 0.00% Interim 25 Nov 2022
29 Jun 2022 $0.0225 0.00% Final 22 Aug 2022
30 Mar 2022 $0.0225 0.00% Interim 20 May 2022
30 Dec 2021 $0.0300 0.00% Interim 25 Feb 2022

HCW ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About HealthCo Healthcare and Wellness REIT

HealthCo Healthcare and Wellness REIT (ASX: HCW) owns and manages a portfolio of commercial health and wellness real estate assets. The REIT is under the umbrella of HMC Capital (ASX: HMC), a listed asset manager that invests on behalf of individuals, large institutions, and super funds.

HealthCo Healthcare and Wellness REIT holds a $1.6 billion portfolio of 36 properties including hospitals, aged care, childcare, life sciences and research facilities as well as primary care and wellness assets. The portfolio covers Queensland, New South Wales, Victoria, and Western Australia with a weighted average lease expiry (WALE) of 12 years. 

HCW Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
09 May 2025 $0.83 $-0.04 -4.62% 3,834,011 $0.85 $0.86 $0.80
08 May 2025 $0.87 $0.01 1.17% 1,944,513 $0.84 $0.87 $0.84
07 May 2025 $0.86 $0.00 0.00% 847,095 $0.84 $0.86 $0.84
06 May 2025 $0.86 $0.01 1.18% 533,081 $0.86 $0.86 $0.85
05 May 2025 $0.85 $-0.02 -2.31% 859,102 $0.87 $0.88 $0.85
02 May 2025 $0.87 $0.01 1.17% 2,896,403 $0.85 $0.87 $0.85
01 May 2025 $0.86 $0.02 2.38% 1,566,040 $0.83 $0.86 $0.83
30 Apr 2025 $0.84 $0.01 1.20% 2,085,987 $0.84 $0.84 $0.83
29 Apr 2025 $0.83 $0.02 2.45% 2,117,907 $0.82 $0.84 $0.81
28 Apr 2025 $0.82 $-0.02 -2.41% 1,134,431 $0.83 $0.83 $0.81
24 Apr 2025 $0.83 $0.00 0.00% 2,471,011 $0.83 $0.83 $0.82
23 Apr 2025 $0.83 $0.01 1.21% 1,231,184 $0.84 $0.84 $0.83
22 Apr 2025 $0.83 $-0.02 -2.37% 878,079 $0.85 $0.85 $0.82
17 Apr 2025 $0.85 $-0.01 -1.17% 1,262,337 $0.85 $0.85 $0.84
16 Apr 2025 $0.86 $0.02 2.40% 1,179,608 $0.84 $0.87 $0.84
15 Apr 2025 $0.84 $-0.01 -1.19% 748,600 $0.84 $0.85 $0.83
14 Apr 2025 $0.84 $0.03 3.68% 1,044,804 $0.82 $0.85 $0.81
11 Apr 2025 $0.82 $-0.04 -4.71% 1,771,330 $0.83 $0.84 $0.81

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Feb 2025 Kelly O'Dwyer Buy 16,377 $16,049
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY25
voluntary non-executive director unit
acquisition arrangement as summarised in
HCW's Product Disclosure Statement dated 2
August 2021.
27 Feb 2025 Joseph Carrozzi Buy 16,079 $15,757
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY25
voluntary non-executive director unit
acquisition arrangement as summarised in
HCW's Product Disclosure Statement dated 2
August 2021.
27 Feb 2025 Natalie Meyenn Buy 19,361 $18,973
As advised by the company. Tranche 1 of 2 of the acquisition of units
pursuant to participation in the FY25
voluntary non-executive director unit
acquisition arrangement as summarised in
HCW's Product Disclosure Statement dated 2
August 2021.
19 Dec 2024 Stephanie Lai Buy 87,500 $88,733
On-market trade.
18 Dec 2024 Stephanie Lai Buy 12,500 $12,875
On-market trade.
02 Sep 2024 Kelly O'Dwyer Buy 12,824 $15,645
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24
voluntary non-executive director unit
acquisition
02 Sep 2024 Joseph Carrozzi Buy 12,513 $15,265
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24
voluntary non-executive director unit
acquisition
02 Sep 2024 Natalie Meyenn Buy 15,310 $18,678
As advised by the company. Tranche 2 of 2 of the acquisition of units
pursuant to participation in the FY24
voluntary non-executive director unit
acquisition
16 May 2024 Christopher Roberts Buy 85,490 $100,878
On-market trade.
16 May 2024 Christopher Roberts Sell 9,636 $11,322
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Christopher Graham Roberts Non-Executive Director Aug 2021
Dr Roberts has over 40 years of experience in the medical device industry serving a number of senior management positions. He was the former CEO of Cochlear from 2004 to 2015 and is presently a member of the Cochlear Foundation Board and a Non-Executive Director of Sigma Healthcare Limited, Clarity Pharmaceuticals Limited, HMC Capital Partners Fund 1, Atmo Biosciences Ltd, Centenary Institute of Medical Research and Nutromics Pty Ltd. He was also the Executive Vice President of ResMed from 1992 to 2003, and a director until 2017. Chris was a former Chair of Research Australia from 2004 to 2010.
Ms Stephanie Mei-Nga Lai Non-Executive Director Aug 2021
Ms Lai e has over 25 years of experience, is a Chartered Accountant and is a former Transaction Services partner of Deloitte and KPMG. She has experience providing due diligence and advisory services, including forecast reviews to listed entities, sovereign wealth funds, wealth managers and private equity. She is Chair of Risk Committee.
Mr David Anthony Di Pilla Non-Executive Director Jul 2021
Mr Pilla has over 30 years of experience in investment banking, strategic advisory and consulting, and corporate leadership as a Director and CEO. During his 20 years of investment banking career, David was Managing Director of UBS Investment Bank for over 15 years and during this time led some of Australia's landmark transactions across corporate M&A, Equity & Debt Capital Markets. Prior to his time at UBS, David reached the position of Vice President, Investment Banking at JP Morgan.
Hon Kelly Megan O'Dwyer Non-Executive Director Aug 2021
Ms O'Dwyer previously served in the Australian Parliament as a Senior Cabinet Minister holding a number of key economic portfolios including Minister for Jobs and Industrial Relations, Minister for Revenue and Financial Services, Minister for Small Business, and Assistant Treasurer. She also served on the Cabinet's Budget Committee (the Expenditure Review Committee) and held the portfolios of Minister for Women, as well as Minister Assisting the Prime Minister with the Public Service. Prior to entering Parliament, Kelly worked in law, government and finance and brings insights across a range of sectors including funds management, superannuation, workplace relations, foreign investment, law and banking.
Mr Joseph Carrozzi Non-Executive ChairmanNon-Executive Director Aug 2021
Mr Carrozzi has over 25 years of experience as a managing partner in the Big 4 professional services firms. He has experience in infrastructure, health and medical research as well as sectors which are highly regulated. He is currently the Chair of the Centenary Institute for Medical Research, the Angus Knight Group, as well as a board member of the National Intermodal Corporation, the NSW Business Chamber, Football Australia, Aurrum Pty Ltd and ServiceGen Pty Ltd. Joseph was formerly Chair of the Sydney Harbour Federation Trust and Deputy Chair of the NSW Institute of Sport. He is also a member of Risk Committee.
Ms Natalie Jane Meyenn Non-Executive Director Aug 2021
Ms Meyenn has over 25 years of experience in financial services and investing globally. She was Head and Chair of the Investment Committee for MLC Private Equity and is currently co-founder of an agriculture investment firm and adviser and/or investment committee member to a small number of asset management, private equity and non-profits including New Energy Nexus and Yielco Investments. She worked in investment banking (M&A, capital markets and public finance) for Goldman Sachs and Bear Stearns in New York and Sydney and for the World Bank on micro-credit, project finance and climate impact mitigation in Asia, Africa and the Pacific Islands. She is also a member of Risk Committee.
Mr Andrew Selim Company SecretaryGeneral Counsel
-
Andrew Selim Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Home Consortium Developments Limited 89,871,409 16.02%
J P Morgan Nominees Australia Pty Limited 80,211,627 14.30%
HSBC Custody Nominees (Australia) Limited 76,429,553 13.62%
Citicorp Nominees Pty Limited 36,237,475 6.46%
Home Consortium Limited 35,034,393 6.24%
BNP Paribas Noms Pty Ltd 29,916,793 5.33%
Netwealth Investments Limited (Wrap Services A/C) 7,033,080 1.25%
National Nominees Limited 5,140,105 0.92%
BNP Paribas Nominees Pty Ltd (HUB24 Custodial Serv Ltd) 4,858,930 0.87%
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 4,444,729 0.79%
HSBC Custody Nominees (Australia) Limited A/C 2 3,273,968 0.58%
HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) 2,540,200 0.45%
Netwealth Investments Limited (Super Services A/C) 2,284,185 0.41%
BNP Paribas Nominees Pty Ltd (Pitcher Partners) 2,282,189 0.41%
Goat Properties Pty Ltd 1,986,390 0.35%
Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 1,609,218 0.29%
Sword Excalibur Equities Pty Ltd (Sword Excalibur EQ 2 A/C) 1,597,222 0.28%
Glengallan Investments Pty Ltd 1,188,249 0.21%
Premium Capital (Aust) Pty Ltd 1,082,000 0.19%
Seymour Group Pty Ltd 1,078,000 0.19%

Profile

since

Note